{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:35:18Z","timestamp":1789504518458,"version":"build-2803163510"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011893","name":"pan american health organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011893","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"united states agency for international development","doi-asserted-by":"crossref","award":["7200AA18CA00040"],"award-info":[{"award-number":["7200AA18CA00040"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Guyana is one of four countries in the Latin American Region where lymphatic filariasis (LF) remains endemic. In preparation for the introduction of a new triple drug therapy regimen (ivermectin, diethylcarbamazine, and albendazole (IDA)) in 2019, an acceptability study was embedded within sentinel site mapping in four regions to assess mass drug administration (MDA) coverage and compliance, acceptability, and perceptions about treatment and disease. The results from this survey would inform the rollout of IDA in Guyana in 2019.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Data collection for the study occurred in August 2019, using a validated questionnaire administered by trained enumerators. Across all regions, a total of 1,248 participants were sampled by the Filarial Mapping team. Four-hundred and fifty-one participants aged over 18 years were randomly selected for participation in an expanded acceptability questionnaire. All data were captured in Secure Data Kit (SDK).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Acceptability was measured using a mean acceptability score. Unadjusted mean scores ranged from 24.6 to 29.3, with 22.5 as the threshold of acceptability. Regional variation occurred across many indicators of interest: self-rated understanding about LF, mechanisms of LF transmission, LF drug safety and history of treatment during MDA. Region IV (Georgetown) recorded higher knowledge about LF, but lower compliance and acceptability. Number of pills was not perceived as a concern.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Acceptability of MDA was good across all four regions under study. Results from this study set a baseline level for key indicators and acceptability, from which the acceptability of IDA can be measured. Regional variations across indicators suggest that localized approaches should be considered for social mobilization and MDA delivery to capture these contextual differences.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pntd.0009596","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T18:17:42Z","timestamp":1632161862000},"page":"e0009596","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Assessing factors influencing communities\u2019 acceptability of mass drug administration for the elimination of lymphatic filariasis in Guyana"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5948-4335","authenticated-orcid":true,"given":"Reza A.","family":"Niles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Thickstun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9127-4212","authenticated-orcid":true,"given":"Horace","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4597-5915","authenticated-orcid":true,"given":"Daniel","family":"Dilliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6001-4960","authenticated-orcid":true,"given":"Clara R.","family":"Burgert-Brucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1432-8109","authenticated-orcid":true,"given":"Emma M.","family":"Harding-Esch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7632-5221","authenticated-orcid":true,"given":"Nikita","family":"Clementson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9353-1748","authenticated-orcid":true,"given":"Annastacia","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Seme","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Morice Trejos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronaldo G. Carvalho","family":"Scholte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-1577","authenticated-orcid":true,"given":"Alison","family":"Krentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,9,20]]},"reference":[{"issue":"9747","key":"pntd.0009596.ref001","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(10)60586-7","article-title":"Lymphatic filariasis and onchocerciasis","volume":"376","author":"MJ Taylor","year":"2010","journal-title":"The Lancet"},{"key":"pntd.0009596.ref002","unstructured":"WHO. Lymphatic filariasis [Internet]. Lymphatic filariasis. 2020 [cited 2020 Oct 31]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lymphatic-filariasis"},{"key":"pntd.0009596.ref003","volume-title":"Lymphatic filariasis: the disease and its control, fifth report of the WHO Expert Committee on Filariasis [meeting held in Geneva from 1 to 8 October 1991]","author":"WHO","year":"1992"},{"issue":"12","key":"pntd.0009596.ref004","doi-asserted-by":"crossref","first-page":"e1366","DOI":"10.1371\/journal.pntd.0001366","article-title":"The Emerging Story of Disability Associated with Lymphatic Filariasis: A Critical Review","volume":"5","author":"LM Zeldenryk","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0009596.ref005","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/tmi.12017","article-title":"Socioeconomic burden of lymphatic filariasis in Georgetown, Guyana","volume":"18","author":"E Tyrell","year":"2013","journal-title":"Trop Med Int Health"},{"issue":"12","key":"pntd.0009596.ref006","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1093\/cid\/ciz671","article-title":"The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs","volume":"70","author":"CG Mathew","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pntd.0009596.ref007","unstructured":"WHO. Global programme to eliminate lymphatic filariasis: progress report, 2019. Geneva: World Health Organization; 2020 Oct p. 509\u201323. (Weekly epidemiological record). Report No.: 43, 2020 95."},{"issue":"23","key":"pntd.0009596.ref008","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMe020136","article-title":"Major progress toward eliminating lymphatic filariasis","volume":"347","author":"E Ottesen","year":"2002","journal-title":"N Engl J Med"},{"issue":"6","key":"pntd.0009596.ref009","first-page":"491","article-title":"Strategies and tools for the control\/elimination of lymphatic filariasis","volume":"75","author":"EA Ottesen","year":"1997","journal-title":"Bull World Health Organ"},{"issue":"2","key":"pntd.0009596.ref010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1517\/14656566.6.2.179","article-title":"Treatment strategies underpinning the global programme to eliminate lymphatic filariasis","volume":"6","author":"JO Gyapong","year":"2005","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"pntd.0009596.ref011","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1365-3156.2000.00620.x","article-title":"Editorial: The Global Programme to Eliminate Lymphatic Filariasis","volume":"5","author":"EA Ottesen","year":"2000","journal-title":"Tropical Medicine & International Health"},{"issue":"11","key":"pntd.0009596.ref012","doi-asserted-by":"crossref","first-page":"e3319","DOI":"10.1371\/journal.pntd.0003319","article-title":"Progress and Impact of 13 Years of the Global Programme to Eliminate Lymphatic Filariasis on Reducing the Burden of Filarial Disease","volume":"8","author":"KD Ramaiah","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0009596.ref013","doi-asserted-by":"crossref","first-page":"e964","DOI":"10.1371\/journal.pntd.0000964","article-title":"Elimination of Neglected Diseases in Latin America and the Caribbean: A Mapping of Selected Diseases","volume":"5","author":"MC Schneider","year":"2011","journal-title":"PLoS Negl Trop Dis."},{"issue":"1","key":"pntd.0009596.ref014","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1186\/s13071-014-0466-x","article-title":"The global distribution and transmission limits of lymphatic filariasis: past and present","volume":"7","author":"J Cano","year":"2014","journal-title":"Parasites & Vectors"},{"issue":"5","key":"pntd.0009596.ref015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1590\/S1020-49892000000500005","article-title":"Lymphatic filariasis in the Caribbean region: the opportunity for its elimination and certification","volume":"7","author":"SC Rawlins","year":"2000","journal-title":"Pan Am J Public Heal"},{"issue":"4","key":"pntd.0009596.ref016","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1017\/S0031182000066646","article-title":"Re-assessing the global prevalence and distribution of lymphatic filariasis","volume":"112","author":"E Michael","year":"1996","journal-title":"Parasitology"},{"issue":"93","key":"pntd.0009596.ref017","first-page":"598","article-title":"Global programme to eliminate lymphatic filariasis: progress report, 2017","volume":"44","author":"WHO","year":"2018","journal-title":"Weekly epidemiological record"},{"key":"pntd.0009596.ref018","first-page":"1","volume-title":"Lymphatic Filariasis Elimination in the Americas Regional Program Manager\u2019s Meeting","author":"PAHO","year":"2010"},{"issue":"7","key":"pntd.0009596.ref019","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2471\/BLT.06.034108","article-title":"Unfulfilled potential: using diethylcarbamazine-fortified salt to eliminate lymphatic filariasis","volume":"85","author":"P Lammie","year":"2007","journal-title":"Bulletin of the World Health Organization"},{"key":"pntd.0009596.ref020","unstructured":"WHO. Global programme to eliminate lymphatic filariasis: progress report, 2018 [Internet]. Geneva: World Health Organization; 2019 Oct [cited 2020 Oct 31] p. 457\u201372. (Weekly epidemiological record). Report No.: 41, 2019, 94. Available from: https:\/\/www.who.int\/publications-detail-redirect\/who-wer9441-457-472"},{"key":"pntd.0009596.ref021","first-page":"14","volume-title":"Guideline: Alternative Mass Drug Administration Regimens to Eliminate Lymphatic Filariasis","author":"WHO","year":"2017"},{"issue":"11","key":"pntd.0009596.ref022","doi-asserted-by":"crossref","first-page":"e2447","DOI":"10.1371\/journal.pntd.0002447","article-title":"A Review of Factors That Influence Individual Compliance with Mass Drug Administration for Elimination of Lymphatic Filariasis","volume":"7","author":"A Krentel","year":"2013","journal-title":"PLOS Neglected Tropical Diseases"},{"issue":"3","key":"pntd.0009596.ref023","doi-asserted-by":"crossref","first-page":"e0009002","DOI":"10.1371\/journal.pntd.0009002","article-title":"A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis","volume":"15","author":"A Krentel","year":"2021","journal-title":"PLOS Neglected Tropical Diseases"},{"issue":"1","key":"pntd.0009596.ref024","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12913-017-2031-8","article-title":"Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework","volume":"17","author":"M Sekhon","year":"2017","journal-title":"BMC Health Services Research"},{"key":"pntd.0009596.ref025","volume-title":"The Social Validity Manual: A Guide to Subjective Evaluation of Behavior Interventions","author":"SL Carter","year":"2009"},{"issue":"3","key":"pntd.0009596.ref026","doi-asserted-by":"crossref","first-page":"e0150259","DOI":"10.1371\/journal.pone.0150259","article-title":"User and Provider Acceptability of Intermittent Screening and Treatment and Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine to Prevent Malaria in Pregnancy in Western Kenya","volume":"11","author":"J Hill","year":"2016","journal-title":"PLOS ONE"},{"issue":"4","key":"pntd.0009596.ref027","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1037\/h0090567","article-title":"The influence of treatment strength information on knowledgeable teachers\u2019 pretreatment evaluations of social skills training methods","volume":"3","author":"L Clark","year":"1988","journal-title":"Professional School Psychology"},{"issue":"5","key":"pntd.0009596.ref028","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/09540120120075275","article-title":"The acceptability of HIV immunization: Examining vaccine characteristics as determining factors","volume":"13","author":"A Liau","year":"2001","journal-title":"AIDS Care"},{"issue":"3","key":"pntd.0009596.ref029","first-page":"227","article-title":"Impact of treatment efficacy and professional affiliation on ratings of treatment acceptability","volume":"32","author":"S Spreat","year":"1994","journal-title":"Ment Retard."},{"issue":"2","key":"pntd.0009596.ref030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0022-4405(90)90007-T","article-title":"Acceptability of time-out: The influence of problem behavior severity, interventionist, and reported effectiveness","volume":"28","author":"DH Tingstrom","year":"1990","journal-title":"Journal of School Psychology"},{"issue":"2","key":"pntd.0009596.ref031","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/019874298400900211","article-title":"Acceptability of Behavioral Interventions Used in Classrooms: The Influence of Amount of Teacher Time, Severity of Behavior Problem, and Type of Intervention","volume":"9","author":"JC Witt","year":"1984","journal-title":"Behavioral Disorders"},{"issue":"2","key":"pntd.0009596.ref032","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s10461-007-9266-z","article-title":"Assessing Microbicide Acceptability: A Comprehensive and Integrated Approach","volume":"12","author":"KM Morrow","year":"2008","journal-title":"AIDS Behav"},{"key":"pntd.0009596.ref033","volume-title":"Monitoring and epidemiological assessment of mass drug administration in global programme to eliminate lymphatic filariasis: a manual for national elimination programmes","author":"WHO","year":"2011"},{"key":"pntd.0009596.ref034","volume-title":"Module 7: The EPI coverage survey","author":"Expanded Programme on Immunization","year":"2008"},{"key":"pntd.0009596.ref035","volume-title":"Research methods in anthropology: qualitative and quantitative approaches","author":"HR Bernard","year":"2011","edition":"5"},{"key":"pntd.0009596.ref036","unstructured":"UX Apps. Random number generator [Internet]. UX Apps; Available from: https:\/\/random-ux.en.aptoide.com\/app"},{"issue":"2","key":"pntd.0009596.ref037","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/biomet\/76.2.297","article-title":"Regression and time series model selection in small samples","volume":"76","author":"CM Hurvich","year":"1989","journal-title":"Biometrika"},{"issue":"1","key":"pntd.0009596.ref038","doi-asserted-by":"crossref","first-page":"e83413","DOI":"10.1371\/journal.pone.0083413","article-title":"Increasing Coverage in Mass Drug Administration for Lymphatic Filariasis Elimination in an Urban Setting: a Study of Malindi Town, Kenya","volume":"9","author":"DW Njomo","year":"2014","journal-title":"PLOS ONE"},{"issue":"1","key":"pntd.0009596.ref039","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1756-3305-3-120","article-title":"High coverage of mass drug administration for lymphatic filariasis in rural and non-rural settings in the Western Area, Sierra Leone.","volume":"3","author":"MH Hodges","year":"2010","journal-title":"Parasites Vectors"},{"key":"pntd.0009596.ref040","volume-title":"Hierarchical modeling and analysis for spatial data","author":"S Banerjee","year":"2004"},{"issue":"9","key":"pntd.0009596.ref041","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/trstmh\/tru057","article-title":"Coverage of, and compliance with, mass drug administration under the programme to eliminate lymphatic filariasis in India: a systematic review","volume":"108","author":"BV Babu","year":"2014","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"1","key":"pntd.0009596.ref042","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13071-016-1311-1","article-title":"Compliance with anthelmintic treatment in the neglected tropical diseases control programmes: a systematic review","volume":"9","author":"KV Shuford","year":"2016","journal-title":"Parasites Vectors"},{"key":"pntd.0009596.ref043","unstructured":"Young, Rebekah Lynn. Don\u2019t Know Responses in Survey Research [Internet]. [University Park, PA]: The Pennsylvania State University; 2012. Available from: https:\/\/etda.libraries.psu.edu\/catalog\/13934"},{"issue":"11","key":"pntd.0009596.ref044","doi-asserted-by":"crossref","first-page":"e0005027","DOI":"10.1371\/journal.pntd.0005027","article-title":"Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two \u2018Endgame\u2019 Districts in Indonesia Using Micronarrative Surveys","volume":"10","author":"A Krentel","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0009596.ref045","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-3156.2009.02443.x","article-title":"Predictors of compliance with a mass drug administration programme for lymphatic filariasis in Orissa State, India 2008","volume":"15","author":"PT Cantey","year":"2010","journal-title":"Tropical Medicine & International Health"},{"issue":"5","key":"pntd.0009596.ref046","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.trstmh.2006.09.002","article-title":"Factors influencing drug compliance in the mass drug administration programme against filariasis in the Western province of Sri Lanka","volume":"101","author":"S Gunawardena","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"6","key":"pntd.0009596.ref047","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1365-3156.2006.01626.x","article-title":"Participation in three consecutive mass drug administrations in Leogane, Haiti","volume":"11","author":"E Mathieu","year":"2006","journal-title":"Tropical Medicine & International Health"},{"key":"pntd.0009596.ref048","first-page":"1","volume-title":"Sociodemographic, Knowledge, and Attitude Determinants of Lymphatic Filariasis Medication Adherence in Subang, Indonesia","author":"M Widawati","year":"2020"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T18:18:59Z","timestamp":1632161939000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009596"}},"subtitle":[],"editor":[{"given":"Marc P.","family":"H\u00fcbner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,20]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0009596","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,20]]}}}